FO-004
/ 3B Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 26, 2025
A study to investigate safety and anti-tumour activity of a Fibroblast Activation Protein (FAP)-targeting radiotracer (177Lu-FO-004) in patients with advanced cancer.
(ANZCTR)
- P1 | N=56 | Not yet recruiting | Sponsor: 3B Pharmaceuticals GmbH
New P1 trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1